论文部分内容阅读
目的:研究疏血通注射液对COPD患者急性加重期肺动脉高压影响的临床效果。方法:选取我院2012年9月—2014年10月收治的64例COPD急性加重期肺动脉高压患者的临床资料,根据数字随机分组法原则,将患者分为两组,每组各32例患者,对照组采用常规治疗,观察组在常规治疗基础上给予疏血通注射液治疗,比较两组患者的肺动脉平均压、内皮素、血栓素B2的变化情况及其治疗效果。结果:1治疗后,观察组的平均肺动脉压、内皮素、血栓素B2指标改善效果优于对照组,对比有统计学意义(P<0.05)。2观察组中,6例患者治疗有效,总有效率为96.9%。对照组,总有效率为81.3%。观察组治疗有效率优于对照组,对比有统计学意义(P<0.05)。结论:疏血通注射液的应用可以使PAH降低,对血小板功能可起到调节作用,是一种可靠的治疗方式,值得临床推广应用。
Objective: To study the clinical effect of Shuxuetong injection on pulmonary hypertension in patients with acute exacerbation of COPD. Methods: The clinical data of 64 patients with acute exacerbation of pulmonary hypertension who were admitted to our hospital from September 2012 to October 2014 were selected. According to the principle of digital randomization, the patients were divided into two groups, 32 patients in each group, The control group was treated with conventional therapy. The observation group was treated with Shuxuetong injection on the basis of routine treatment. The changes of pulmonary arterial pressure, endothelin, thromboxane B2 and the therapeutic effect were compared between the two groups. Results: After treatment, the average pulmonary arterial pressure, endothelin and thromboxane B2 in the observation group were better than those in the control group (P <0.05). 2 observation group, 6 patients were treated effectively, the total effective rate was 96.9%. The control group, the total effective rate was 81.3%. The treatment group was better than the control group, the difference was statistically significant (P <0.05). Conclusion: The application of Shuxuetong injection can reduce PAH and play a regulatory role on platelet function, which is a reliable treatment and worthy of clinical application.